PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
March 14, 2026Neuro-Oncology PediatricsOpen Access

DMG-59. Preclinical efficacy of JAK2/IRAK1/ACVR1 inhibitor pacritinib against diffuse midline glioma (DMG)

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMatthew C. BieryDLDavina LauLWLily I. Winter

Discussion

Loading...

Member takes

Overview

Preclinical studies demonstrate pacritinib reduces IC50 and induces apoptosis in diffuse midline glioma models, suggesting therapeutic potential.

Key Points

  • To evaluate the preclinical efficacy of pacritinib in treating diffuse midline glioma (DMG).
  • Utilized patient-derived diffuse intrinsic pontine glioma (DIPG) models with various H3 mutations.
  • Conducted viability and apoptosis assays, as well as signaling analysis.
  • Analyzed JAK/STAT pathway signaling using western blot for pSTAT3, pSTAT5, and pJAK2 levels.
  • Pacritinib demonstrated an IC50 of 1.47 uM in models after 96 hours.
  • Robust apoptotic responses were observed, peaking at 34 hours with a caspase 3/7 assay.
  • Significant reduction in pSTAT3, pSTAT5, and pJAK2 levels indicates effective JAK2 inhibition.

Cite This Study

Biery et al. (2025) studied this question.

synapsesocial.com/papers/69b4ba3618185d8a39802f9ahttps://doi.org/10.1093/neuped/wuaf001.089
View Full Paper
Ask AI
Bookmark
Share